Shortage of Peritoneal Dialysis Solution and the Food and Drug Administration's Response

被引:16
作者
Jensen, Valerie [1 ]
Throckmorton, Douglas C. [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2015年 / 10卷 / 08期
关键词
D O I
10.2215/CJN.12061214
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Although the number of new drug shortages has been lower in recent years than in the past, severe shortages have occurred that have affected large numbers of patients. A new law entitled the Food and Drug Administration Safety and Innovation Act was enacted in July of 2012, which requires companies to notify the Food and Drug Administration of anticipated shortages. This notification requirement has allowed the Food and Drug Administration to work closely with manufacturers earlier to mitigate and, often, prevent shortages. However, not all shortages are able to be prevented, and the shortage of peritoneal dialysis solution is one that has had a significant effect on patients. The Food and Drug Administration continues to use all available tools to address this shortage with manufacturers, including temporary availability of imported peritoneal dialysis solution from Ireland. Mitigating shortages is a top priority for the Food and Drug Administration, and communication with all stakeholders is essential.
引用
收藏
页码:1484 / 1486
页数:3
相关论文
共 3 条
  • [1] [Anonymous], CURR DRUG SHORT
  • [2] FDA, FDA PRESS ANN
  • [3] Drug Shortages:The Cycle of Quantity and Quality
    Kweder, S. L.
    Dill, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (03) : 245 - 251